Johnson & Johnson Sues To Stop Generic Risperdal

Law360, New York (June 30, 2006, 12:00 AM EDT) -- A subsidiary of Johnson & Johnson has filed a federal patent infringement lawsuit in an attempt to thwart a Canadian pharmaceutical company’s efforts to introduce a generic version of Risperdal, the latest in a series of suits filed by J&J to protect the market for its blockbuster antipsychotic drug.

The lawsuit, filed on behalf Belgian J&J subsidiary Janssen Pharmaceutica N.V. and its New Jersey-based unit, Jansen L.P., charges Apotex Inc. with infringing on U.S. Patent Number 4,804,663. That patent covers risperidone, which is marketed by Janssen...
To view the full article, register now.